MDR1 polymorphisms associated with risk and survival in diffuse large B-cell lymphoma

References

• Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417–1429.
   PubMed Web of Science ®Google Scholar
• Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008;8:22–33.
   PubMed Web of Science ®Google Scholar
• Blinder V, Fisher SG. The role of environmental factors in the etiology of lymphoma. Cancer Invest 2008;26:306–316.
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361–398.
   PubMed Web of Science ®Google Scholar
• Ueda K. ABC proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem 2011;75:401–409.
   PubMed Web of Science ®Google Scholar
• Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010;12:628–636.
   PubMed Web of Science ®Google Scholar
• Schaich M, Soucek S, Thiede C, et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005;128:324–332.
   PubMed Web of Science ®Google Scholar
• Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2000;18:2685–2694.
   PubMed Web of Science ®Google Scholar
• Li L, Su LP, Ma L, et al. [Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi 2009;31:199–202.
   PubMedGoogle Scholar
• Cascorbi I. P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011:261–283.
   Google Scholar
• Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97: 3473–3478.
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Hishinuma T, Endo N, et al. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int J Gynecol Cancer 2006;16:979–985.
   PubMed Web of Science ®Google Scholar
• Green H, Soderkvist P, Rosenberg P, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 2009;104:130–137.
   PubMed Web of Science ®Google Scholar
• Hemauer SJ, Nanovskaya TN, Abdel-Rahman SZ, et al. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms. Biochem Pharmacol 2010;79:921–925.
   PubMed Web of Science ®Google Scholar
• Erdelyi DJ, Kamory E, Zalka A, et al. The role of ABC-transporter gene polymorphisms in chemotherapy induced immunosuppression, a retrospective study in childhood acute lymphoblastic leukaemia. Cell Immunol 2006;244:121–124.
   PubMed Web of Science ®Google Scholar
• Cizmarikova M, Wagnerova M, Schonova L, et al. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J 2010;10:62–69.
   PubMed Web of Science ®Google Scholar
• Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006;24:3789–3798.
   PubMed Web of Science ®Google Scholar
• Green H, Soderkvist P, Rosenberg P, et al. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 2006;12: 854–859.
   PubMed Web of Science ®Google Scholar
• Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024–2027.
   PubMed Web of Science ®Google Scholar
• Ni LN, Li JY, Miao KR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 2011;28:265–269.
   PubMed Web of Science ®Google Scholar
• Yu B, Hu LL. MDR1 gene single nucleotide polymorphism in southern China Han population. Acta Sci Nat Uni Sunyatseni 2011;50: 93–98.
   Google Scholar
• Hu LL, Wang XX, Chen X, et al. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. Carcinogenesis 2007;28:1740–1744.
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Meaden ER, Hoggard PG, Maher B, et al. Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1329–1332.
   PubMed Web of Science ®Google Scholar
• Maggio-Price L, Shows D, Waggie K, et al. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am J Pathol 2002;160:739–751.
   PubMed Web of Science ®Google Scholar
• Koyama T, Nakamura T, Komoto C, et al. MDR1 T-129C polymorphism can be predictive of differentiation, and thereby prognosis of colorectal adenocarcinomas in Japanese. Biol Pharm Bull 2006;29:1449–1453.
   PubMed Web of Science ®Google Scholar
• Pan JH, Han JX, Wu JM, et al. MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 2009;78:49–55.
   PubMedGoogle Scholar
• Vinolas N, Provencio M, Reguart N, et al. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011;71:191–198.
   PubMed Web of Science ®Google Scholar
• Huang MY, Huang ML, Chen MJ, et al. Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy. Pharmacogenet Genomics 2011;21:18–25.
   PubMed Web of Science ®Google Scholar
• Kim DH, Park JY, Sohn SK, et al. Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 2006;118:2195–2201.
   PubMed Web of Science ®Google Scholar
• Schaefer M, Roots I, Gerloff T. In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms. Pharmacogenet Genomics 2006;16: 855–861.
   PubMed Web of Science ®Google Scholar
• Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189–199.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sakaeda T, Horinouchi M, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002;71: 297–303.
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315: 525–528.
   PubMed Web of Science ®Google Scholar
• Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002;19: 1581–1585.
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001;18:1400–1404.
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Mlynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004;72:314–321.
   PubMed Web of Science ®Google Scholar
• Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res 2002;62:4955–4962.
   PubMed Web of Science ®Google Scholar
• van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, et al. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 2006;80:427–439.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009;15:4750–4758.
   PubMed Web of Science ®Google Scholar